Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma

Abstract The Cooperative German Paediatric Liver Tumour Study HB89 was conceived to evaluate the efficiency and toxicity of ifosfamide, cisplatin and doxorubicin (IPA) in children with resectable and non-resectable hepatoblastoma (HB) and to determine late sequelae including tubular nephropathy of tumour treatment. The study also assessed the results of a surgical strategy, which adapts the procedure at the initial operation to the tumour's extension in the liver. The relationship of the tumours' histological differentiation to response to chemotherapy was also examined. Patients with a HB restricted to one: liver lobe underwent primary resection. Larger tumours were initially treated with IPA chemotherapy and resected at second-look surgery. All patients received IPA adjuvantly after tumour resection. The IPA regimen consisted of ifosfamide 3.5 g/m 2 (over 72 h days 1–3), cisplatin 100 mg/m 2 (over 5 days 4–8) and doxorubicin 60 mg/m 2 (over 48 h, days 9–10). Median followup of survivors was 64 months (range 28–82). Long-term disease-free survival (DFS) was for stage I: 21 21 ; stage II: 3 6 ; stage III: 28 38 ; and stage IV: 2 7 (overall 75%). Severe surgical complications occurred in 15% ( 4 27 ) of primary and 21% ( 8 38 ) of secondary resections with no lethality. 44 45 stage III IV HB displayed PR after two IPA courses. Drug resistance developed in 8 12 tumours after four or five chemotherapy courses. Acute toxicity was observed in 34 242 (14%) IPA courses. Late sequelae were found in 7 54 (13%) of survivors, and subclinical renal tubulopathy occurred in 7 41 investigated patients (17%). Despite a more favourable prognosis in pure fetal and predominantly fetal histology, statistical analysis revealed no relationship between tumour differentiation and response to chemotherapy. In conclusion, IPA chemotherapy in combination with delayed surgery was highly effective in the treatment of HB.